Solana Co HSDT
Biotechnology: Electromedical & Electrotherapeutic Apparatus · data as of November 13, 2026
Solana Co (HSDT) is a healthcare company listed in the US with a market value of about $109M. In the twelve months to September 30, 2026 it had revenue of $15M and net income of $301M, a net margin of 2040.4%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 0.0, 5-year revenue growth of 56% a year, a 5-year average ROIC of -449%.
About Solana Co
Solana Co is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus. Revenue went from $478000 in 2018 to $6M in 2025, growth of about 43.6% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 6187636% over three years (dilution for shareholders). It spends 58% of revenue on research and development.
Score: 2.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15M | $6M | $520000 | $644000 | $787000 | $522000 | $661000 | $1M | $478000 | — | — |
| Net income | $301M | -$41M | -$12M | -$9M | -$14M | -$18M | -$14M | -$10M | -$29M | -$28M | -$7M |
| Free cash flow | -$71M | — | -$11M | -$10M | -$14M | -$13M | -$12M | -$21M | -$20M | -$20M | — |
| EPS (diluted) | $87.97 | $-0.62 | $-1094.09 | $-3676.68 | $-13163.81 | $-93184.39 | $-148994.02 | $-164019.68 | $-556834.03 | $-662897.65 | $-53031.81 |
| Net margin | 2040.4% | -679.6% | -2258.1% | -1374.2% | -1788.1% | -3473.6% | -2137.7% | -653.8% | -5988.1% | — | — |
| ROIC | — | -81.0% | -1298.1% | -516.3% | -187.8% | -161.1% | -363.1% | -370.8% | -199.7% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $3.00, 73% above the current price; targets range from $3.00 to $3.00; the consensus rating is “Strong buy”; expected EPS is $-0.74 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Solana Co’s P/E ratio?
About 0.0, based on the last twelve months of diluted earnings per share.
Does Solana Co pay a dividend?
Not currently.
Is Solana Co a good stock to buy?
We do not give buy or sell advice. Solana Co scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.